Serum levels of IL-6 and TNF-alpha correlate with clinicopathological features and patient survival in patients with prostate cancer.
Michalaki V, Syrigos K, Charles P, Waxman J. · 2004
Read Serum levels of IL-6 and TNF-alpha correlate with clinicopathological features and patient survival in patients with prostate cancer. by Michalaki V, Syrigos K, Charles P, Waxman J. (2004) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc2409519.txt.
Introduction
Michalaki, Syrigos, Charles, and Waxman measured two immune signal proteins in prostate cancer patients in 2004. The proteins, IL-6 and TNF-alpha, are cytokines, messengers that can help tumors grow and spread. The study covered 80 patients split by disease bulk, plus 38 healthy controls.
Blood IL-6 in patients with spread disease averaged 9.3 picograms per millilitre, versus 1.3 in patients with contained disease, a gap the tests rated highly significant. TNF-alpha showed the same pattern, at 6.3 versus 1.1 in the same units. Both rose in step with how far the cancer had spread. In 40 patients whose cancer returned, both signals climbed at the moment a standard marker, PSA, signalled progression. The authors suggested tracking the pair alongside other markers of disease activity.
Catalog record
| CREATOR | Michalaki V, Syrigos K, Charles P, Waxman J. |
|---|---|
| YEAR | 2004 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 26 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Serum levels of IL-6 and TNF-α correlate with clinicopathological features and patient survival in patients with prostate cancer By V Michalaki, K Syrigos, P Charles, J Waxman Published in: British Journal of Cancer DOI: 10.1038/sj.bjc.6601814 ABSTRACT Interleukin-6 (IL-6) and tumour necrosis factor-alpha (TNF-α) are important multifunctional cytokines involved in tumour growth and metastasis. In this study, we have measured serial levels of serum IL-6 and TNF-α in prostate cancer patients. A total of 80 patients with carcinoma of the prostate and 38 controls were studied. Three patient groups, with small bulk localised, large volume localised and metastatic prostate cancer, were assessed. Serum IL-6 and TNF-α levels were measured and correlated with clinicopathological variables and patient survival. Serial changes in these cytokines were also assessed and related to disease progression in 40 patients with recurrent prostate cancer. Serum IL-6 levels in patients with metastatic disease (9.3±7.8 pg ml−1) were higher than those in patients with localised disease (1.3±0.8 pg ml−1, P<0.001). Significantly elevated levels of TNF-α were found in metastatic disease (6.3±3.6 pg ml−1) compared with localised disease (1.1±0.5 pg ml−1, P<0.001). The levels of both cytokines were directly correlated with the extent of the disease. Serial analysis in 40 patients with recurrent tumours showed that both cytokines became elevated at the point of prostate-specific antigen progression. In conclusion, these results suggest that IL-6 and TNF-α correlate with the extent of disease in patients with prostate cancer and may be monitored in conjunction with other disease markers. Prostate cancer is the most common cancer in men in the Western world and the second most common cause of male cancer deaths. The progression of prostate cancer to a metastatic state and to hormone independence is thought of as a multi-step process involving growth factors, hormones and cytokines (Bok and Small, 2002; Huss et al, 2003). Although there are clear descriptions of the relationship of cytokines to the development and progression of many cancers, there are few published observations relevant to prostate cancer. Surprisingly perhaps for a tumour where there is such clear evidence of a primary hormonal basis to its development, there is emerging evidence of cytokine involvement. IL-6 and TNF-α, two cytokines with multiple and overlapping biological properties, are involved in prostate cancer development (Shariat et al, 2001; Smith et al, 2001). This involvement of IL-6 at a cellular level with the processes of cancer control is reflected by the results of serum studies of cancer patients, where IL-6 may reflect prognosis and tumour load. Elevated IL-6 levels have been associated with advanced stage and metastasis-related morbidity (Adler et al, 1999; Nakashima et al, 2000; Wise et al, 2000). Thus, it has been recently reported that patients with metastatic ovarian cancer and patients with metastatic renal cell carcinoma have higher serum IL-6 levels than those without disseminated disease (Blay et al, 1992; Scambia et al, 1995). It has also been demonstrated that elevated IL-6 levels are associated with a poor prognosis in tumours such as non-small-cell lung cancer. The ontological role of IL-6 in this process is not known (De Vita et al, 1998). Studies of IL-6 in prostate carcinoma provide support for the hypothesis that direct local production of IL-6 by malignant cells significantly contributes to elevated serum levels (Deeble et al, 2001). IL-6 and TNF-α are considered the major mediators of a network of interactive signals. TNF-α is a pleiotropic cytokine, which like IL-6 has been shown to be associated with cancer progression. It is of interest that many androgen-insensitive prostate cancer cells are TNF-α insensitive. This may be because of the upregulation of a series of antiapoptotic genes involved in a network of paracrine and autocrine loops that modulate prostate carcinoma cell activity, and these include the nuclear factor-kappaβ (NF-κβ) family of transcription factors (Muenchen et al, 2000). In a series of 122 patients with renal cell carcinoma, Yoshida et al (2002) demonstrated that serum levels of TNF-α directly correlated with advanced stage grouping as compared with controls, and suggested that TNF-α could be useful in the early diagnosis of the disease. There has been a single study by Nakashima et al (1998), where TNF-α has been shown to be associated with prostate cancer progression. Serum TNF-α activity was positive in 76% of the patients with relapsed disease who had a significantly higher mortality rate than those with undetectable serum TNF-α levels. In this study, we measured the serum levels of IL-6 and TNF-α in prostate cancer patients, using a highly sensitive ELISA kit, in an attempt to define their association with clinicopathological features and clinical outcome. MATERIALS AND METHODS Patients A total of 80 men with prostate cancer (mean age 74.5±7.5 years) were included in this prospective study and compared with two normal control groups, consisting of 12 men presenting for prostate cancer screening who had no prior history of cancer or chronic disease, a normal digital rectal examination and a prostate-specific antigen (PSA) of less than 2.0 ng ml−1, which is in the PSA range with an estimated prostate cancer detection probability of less than 1% in the first 4 years after screening (Smith et al, 1996), and 26 patients with biopsy-proven benign prostatic hyperplasia (1). The mean control age was 67.5±6.8 years. All patients had histological confirmation of the diagnosis of prostate cancer by needle biopsy or by transurethral resection of the prostate. Each patient was staged by clinical examination, bone scanning and computed tomography of the abdomen and pelvis. For the histologic grade the Gleason scoring was used. No patients had evidence of active infection or inflammatory disease. To further evaluate the association between IL-6 and TNF-α and the progression of the disease, we assessed the serial changes of both cytokines in patients with recurrent disease. Therefore, at the time of the study, three samples from each patient with locally advanced or metastatic cancer were collected. The samples were chosen to represent the time points of presentation prior to treatment, the first evidence of PSA increase beyond the normal range and disease progression. Out of 26 patients with localised disease, 12 were initially treated with radiation therapy or surgery, whereas all patients with locally advanced or metastatic disease were treated with endocrine therapy using a luteinising hormone-releasing analogue and flutamide. Neither patients with metastatic disease nor patients with localised disease were treated before serum collection. Sample collection and cytokine measurements Blood samples were prospectively collected with the appropriate Ethical Committee permissions, from patients attending Oncology Outpatients Clinics at the Hammersmith Hospital. Each sample had been collected in a Vacutainer, (Becton Dickinson, Plymouth, UK) and serum was separated within 1 h of blood collection after spinning for 15 min at 1500 g. The serum was stored without preservative at −70°C and then thawed just prior to testing (2). Serum IL-6 and TNF-α concentrations were determined using the commercially available enzyme-linked immuno-sorbent assay (ELISA), US (Ultra sensitive), kit supplied by Biosource International (CA, USA). The assays employ the quantitative sandwich enzyme immunoassay technique using recombinant human IL-6 and TNF-α, with antibodies raised against the recombinant proteins, respectively. The IL-6 ELISA assay has a performance sensitivity of less than 0.16 pg ml−1 with the minimum detectable level at 104 fg ml−1. The TNF-α assay has a performance